Abstract 3213: Selective killing of advanced prostate cancer cells by targeting the Warburg effect and autophagy

2012 ◽  
Author(s):  
Hua Xiong ◽  
Xiaolan Guo ◽  
Yanmei Zou ◽  
Lei Wang ◽  
Yan Cheng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Warburg Effect ◽  
Advanced Prostate Cancer ◽  
Prostate Cancer Cells ◽  
The Warburg Effect

scholarly journals The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells

2013 ◽  
Vol 25 (4) ◽  
pp. 1011-1017 ◽  
Author(s):  
David G. Watson ◽  
Francesca Tonelli ◽  
Manal Alossaimi ◽  
Leon Williamson ◽  
Edmond Chan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Warburg Effect ◽  
Prostate Cancer Cells ◽  
Sphingosine Kinases ◽  
The Warburg Effect

A Selective ERRα/γ Inverse Agonist, SLU-PP-1072, Inhibits the Warburg Effect and Induces Apoptosis in Prostate Cancer Cells

2020 ◽  
Vol 15 (9) ◽  
pp. 2338-2345
Author(s):  
Emmalie Schoepke ◽  
Cyrielle Billon ◽  
Keith M. Haynes ◽  
Amer Avdagic ◽  
Sadichha Sitaula ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Warburg Effect ◽  
Inverse Agonist ◽  
Prostate Cancer Cells ◽  
The Warburg Effect

scholarly journals Phellinus Linteus Extract Sensitizes Advanced Prostate Cancer Cells to Apoptosis in Athymic Nude Mice

PLoS ONE ◽  
2010 ◽  
Vol 5 (3) ◽  
pp. e9885 ◽  
Author(s):  
Takanori Tsuji ◽  
Wei Du ◽  
Takashi Nishioka ◽  
Lihua Chen ◽  
Daisuke Yamamoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Nude Mice ◽  
Advanced Prostate Cancer ◽  
Phellinus Linteus ◽  
Prostate Cancer Cells ◽  
Athymic Nude Mice

Abstract 770: MiR628-5p targets Jagged 1 and inhibits growth, stemness and invasiveness of advanced prostate cancer cells

2019 ◽  
Author(s):  
Leslimar Rios-Colon ◽  
Juliet Chijioke ◽  
Anvesha Srivastava ◽  
Malathi Ramalinga ◽  
Habib Kedir ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Advanced Prostate Cancer ◽  
Prostate Cancer Cells

Abstract 770: MiR628-5p targets Jagged 1 and inhibits growth, stemness and invasiveness of advanced prostate cancer cells

2019 ◽  
Author(s):  
Leslimar Rios-Colon ◽  
Juliet Chijioke ◽  
Anvesha Srivastava ◽  
Malathi Ramalinga ◽  
Habib Kedir ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Advanced Prostate Cancer ◽  
Prostate Cancer Cells

scholarly journals The Enzymatic Activity of Apoptosis-inducing Factor Supports Energy Metabolism Benefiting the Growth and Invasiveness of Advanced Prostate Cancer Cells

2012 ◽  
Vol 287 (52) ◽  
pp. 43862-43875 ◽  
Author(s):  
Eric M. Lewis ◽  
Amanda S. Wilkinson ◽  
Jacqueline S. Jackson ◽  
Rohit Mehra ◽  
Sooryanarayana Varambally ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Energy Metabolism ◽  
Enzymatic Activity ◽  
Cancer Cells ◽  
Advanced Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Apoptosis Inducing Factor

HN1 interacts with γ-tubulin to regulate centrosomes in advanced prostate cancer cells

Cell Cycle ◽  
2021 ◽  
pp. 1-22
Author(s):  
Lokman Varisli ◽  
Aadil Javed ◽  
Bilge Esin Ozturk ◽  
Gencer Kaan Akyuz ◽  
Gulevin Takir ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Advanced Prostate Cancer ◽  
Prostate Cancer Cells

The application of theranostics in different stages of prostate cancer

2021 ◽  
Author(s):  
Omar Alghazo ◽  
Renu Eapen ◽  
Samantha Koschel ◽  
Marcus Cumberbatch ◽  
James Buteau ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Advanced Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Prostate Cancer Cells ◽  
New Approach ◽  
Castration Resistant ◽  
Preclinical Trials ◽  
Treat Prostate Cancer ◽  
Castrate Resistant

Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is still considered the lethal stage of the disease. Theranostics combines a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. The most studied radioligand is 177Lu-PSMA-617, which targets PSMA, a protein found in prostate cancer cells. This new approach has shown promising results in treating metastatic castration-resistant prostate cancer. Currently, many trials are using PSMA-targeting radioligands in combination with conventional therapies in advanced prostate cancer or even in the earlier stages of the disease. Other preclinical trials are exploring the possibility of using newer ligands or radioisotopes to treat prostate cancer to increase the specificity and efficacy of this treatment.

Sign in / Sign up

Export Citation Format

Share Document